INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
70.07
-0.45 (-0.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close70.52
Open70.47
Bid67.99 x 100
Ask71.35 x 100
Day's Range69.93 - 71.18
52 Week Range61.30 - 140.11
Volume1,373,005
Avg. Volume2,240,725
Market Cap14.841B
Beta1.12
PE Ratio (TTM)N/A
EPS (TTM)-1.53
Earnings DateMay 1, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est91.47
Trade prices are not sourced from all markets
  • MARKETS: Welcome to the low volume, low liquidity algo-driven market
    Yahoo Finance Video9 days ago

    MARKETS: Welcome to the low volume, low liquidity algo-driven market

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • Motley Fool3 days ago

    What Incyte's Phase 3 Fail Means for Immuno-Oncology

    Incyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.

  • NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure
    Investor's Business Daily3 days ago

    NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure

    NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.

  • Motley Fool3 days ago

    What's Next for Incyte?

    With a key pipeline drug nixed, Incyte has a few more question marks on the horizon than it did before.

  • MarketWatch3 days ago

    NewLink shares fall on late-stage trial changes

    NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...

  • The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
    Zacks3 days ago

    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

    The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

  • Motley Fool6 days ago

    What Happened With Incyte's IDO Inhibitor Flop

    Investor confidence in epacadostat was through the roof, and the drug's phase 3 flop crushed the stock in a big way.

  • Pharma M&A Active This Week: 4 Potential Buyout Targets
    Zacks6 days ago

    Pharma M&A Active This Week: 4 Potential Buyout Targets

    Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.

  • Incyte: S&P 500’s Top Gainer on April 12
    Market Realist6 days ago

    Incyte: S&P 500’s Top Gainer on April 12

    The S&P 500’s top gainers on April 12 were: Incyte (INCY) gained 5.3%. Micron Technology (MU) gained 4.2%. Host Marriott Financial Trust (HST) gained 4.1%. Deere & Company (DE) gained 4.1%. Discovery (DISCK) gained 3.9%. Incyte 

  • Business Wire6 days ago

    Incyte to Report First Quarter Financial Results

    Incyte Corporation announced today that it has scheduled its first quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 1, 2018.

  • Motley Fool7 days ago

    Why One Drug Flop Tanked Incyte's Stock

    Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.

  • Barrons.com7 days ago

    The Biggest Movers: Incyte Excites; L Brands Slides

    Incyte (INCY) popped to the top of among S&P 500 stock performers, helped by an analyst upgrade. Incyte added $3.54, or 5.3%, to $69.83.  The S&P 500 gained 21.80 points, or 0.83%, to 2663.99. UBS's Carter ...

  • Why GoPro, Incyte, and Wynn Resorts Jumped Today
    Motley Fool7 days ago

    Why GoPro, Incyte, and Wynn Resorts Jumped Today

    Find out which of these companies jumped on takeover chatter.

  • Investopedia7 days ago

    3 Biotech Stocks Analysts Have Been Too Bullish On

    Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.

  • Incyte Advances R&D Strategy with Multiple Partnerships
    Market Realist7 days ago

    Incyte Advances R&D Strategy with Multiple Partnerships

    In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.

  • Why Did Bristol-Myers Squibb Stock Fall More Than 3% on April 6?
    Market Realist7 days ago

    Why Did Bristol-Myers Squibb Stock Fall More Than 3% on April 6?

    On April 6, 2018, Incyte (INCY) stock fell nearly 20%, triggered by news of the failure of the clinical trial for its skin cancer drug. The trial is for the assessment of the combo-therapy approach of Incyte’s epacadostat and Merck’s (MRK) Keytruda for the treatment of skin cancer. The Phase 3 trial results were unexpectedly found to yield unsuccessful results since it did not achieve the main goal of the study.

  • Olumiant Could Boost Incyte’s Revenues
    Market Realist7 days ago

    Olumiant Could Boost Incyte’s Revenues

    In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis (or RA) and who did not respond sufficiently or could not tolerate disease-modifying antirheumatic drugs (or DMARDs). In July 2017, the drug was approved by the Japan Ministry of Health, Labor, and Welfare for RA patients who don’t respond sufficiently to standard-of-care treatment options. The drug is also approved in Switzerland for the RA indication.

  • Incyte Has Diversified Its Revenues across Multiple Product Lines
    Market Realist7 days ago

    Incyte Has Diversified Its Revenues across Multiple Product Lines

    Incyte (INCY) expects to report GAAP (generally accepted accounting principles) and non-GAAP revenues in the range of $80 million to $85 million from the sale of Iclusig in fiscal 2018. In June 2016, Incyte entered a licensing agreement with Ariad Pharmaceuticals for the development and commercialization of kinase inhibitor, Iclusig, in the European Union and 22 other countries.

  • Jakafi Continues to Be Strong Growth Driver for Incyte in 2018
    Market Realist8 days ago

    Jakafi Continues to Be Strong Growth Driver for Incyte in 2018

    Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.

  • Incyte Expected to Report Robust Revenue Growth in Fiscal 2018
    Market Realist8 days ago

    Incyte Expected to Report Robust Revenue Growth in Fiscal 2018

    In 2017, Incyte (INCY) reported total revenues of close to $1.5 billion, which was year-over-year (or YoY) growth of around 38.9%. The company earned revenues close to $1.1 billion from the sale of Jakafi, a JAK1/JAK2 inhibitor, in the US, and $152 million as royalties received from Novartis (NVS) on the sale of Jakafi, marketed as Jakavi, in international markets. Wall Street analysts have projected Incyte’s fiscal 2018 revenues to be close to $1.8 billion, which is a YoY rise of around 16.9%.

  • What Analysts Recommend for Incyte in April 2018
    Market Realist8 days ago

    What Analysts Recommend for Incyte in April 2018

    On April 6, 2018, Incyte (INCY) reported unfavorable results from its phase 3 ECHO-301/KEYNOTE-252 study, which evaluated the potential of the company’s investigational therapy, epacadostat, combined with Merck’s (MRK) Keytruda, in patients suffering from unresectable or metastatic melanoma as compared to those treated with Keytruda monotherapy. The trial failed to meet its first primary endpoint of improvement in progression-free survival and is also not expected to meet the second primary endpoint of overall survival. This news has had a drastic impact on Incyte’s stock, which fell ~22.9% from $83.07 on April 5, 2018, to $64.02 on April 6, 2018, and reduced the company’s market capitalization by approximately $3.5 billion.

  • Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
    Zacks8 days ago

    Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis

    The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.

  • Is Beaten-Down Incyte Corporation Stock a Buy Now?
    Motley Fool8 days ago

    Is Beaten-Down Incyte Corporation Stock a Buy Now?

    A clinical-trial flop with epacadostat isn't the end of the world for Incyte.

  • Morningstar8 days ago

    10 Cheap, High-Quality Stocks With Major Growth Catalysts

    Take a look at Morningstar analysts' nine 'exponential technology' themes and some undervalued stocks poised to benefit from them.

  • NewLink Shares Plunge After Incyte & Merck's Study Fails
    Zacks10 days ago

    NewLink Shares Plunge After Incyte & Merck's Study Fails

    Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.